Ocular Therapeutix Stock Jumps 27% on Accelerated Drug Approval Plans

Ocular Therapeutix (OCUL) shares surge 27% after announcing plans to fast-track FDA submission for Axpaxli, a promising new treatment for wet age-related macular degeneration affecting millions.